More specifically, we observed Pax-5 expression in: 93% in normal breast; 100% in all invasive ductal and lobular carcinoma; 86% in mucinous adenocarcinoma; and, 100% of ductal carcinoma in situ (Supplementary Table 2). Here, PAX5 is linked to mucinous adenocarcinoma.